Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

HOERSHOLM, Denmark and SAN DIEGO, April 26 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

High cholesterol is a major risk factor for coronary heart disease, heart attack and stroke. According to the World Health Organization, high cholesterol is estimated to cause 18% of strokes and 56% of heart disease, globally and amounts to approximately 4.4 million deaths and 40.4 million disability-adjusted life years(1).

Santaris Pharma A/S presented preclinical data on SPC5001 last month at the PCSK9 Conference "From gene to therapeutics" in Nantes, France where many top pharmaceutical companies gathered to discuss efforts to develop therapies aimed at inhibiting the important new target PCSK9, a protein involved in regulating LDL (low-density lipoprotein) or "bad" cholesterol in the blood.

Data presented by Santaris Pharma A/S scientists showed that SPC5001 provided potent, specific and long-lasting inhibition of PCSK9 and lowered mean LDL cholesterol by 50% in non-human primates with a sustained reduction of 74% in the highest responder. SPC5001 did not change HDL (high-density lipoprotein) levels or the "good" cholesterol in the blood(2). The preclinical data suggest that SPC5001 has the potential to provide patients with a new treatment opti
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
(Date:3/27/2015)... RI (PRWEB) March 27, 2015 Earlier ... for the promotion of hair regrowth in adult men ... classifications I-II or Norwood Hamilton classifications of IIa-V and ... an industry plagued by products that over-promise and under-deliver, ... Capillus272Pro™, renewing faith and confidence among more than 80 ...
(Date:3/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... in accordance with Securities and Exchange Commission rule 10b5-1. ... Corporation, is a minority owner of this entity that ... Herbert does not have control of this entity, but ... for a portion of the shares owned by that ...
(Date:3/27/2015)... , March 27, 2015 Working ... Free Hospital in London , Richmond Pharmacology ... a global Phase 3 study for an investigational RNAi therapeutic ... orphan disease affecting the nerves and heart. ... Detail Based at St Georges University of ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Neogen CEO adopts 10b5-1 Trading Plan 2
... TORAYMYXIN™ IN SEPTIC SHOCK ... ... --> ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Oct. 19 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin ... a fast-growing, profitable developer, manufacturer and seller of medicine ... announced today that its wholly owned subsidiary, En Ze ... the State Intellectual Property Office of the People,s Republic ...
... The US and European medical technology industry struggled ... but managed to improve overall net income by nearly ... While medtech has fared better than many industries in ... strain on the industry,s long-standing business model. These and ...
Cached Biology Technology:SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 2SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 3SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 4SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 5SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 6SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 7SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 8SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK 9Lotus Pharmaceuticals Announces New Patent for Controlled-Release Diabetes Drug 2Lotus Pharmaceuticals Announces New Patent for Controlled-Release Diabetes Drug 3Medtech Industry Successfully Weathering Challenges of Economic Downturn 2Medtech Industry Successfully Weathering Challenges of Economic Downturn 3Medtech Industry Successfully Weathering Challenges of Economic Downturn 4Medtech Industry Successfully Weathering Challenges of Economic Downturn 5
(Date:3/2/2015)... 2, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new implementation of ... enable rapid and secure transactions and reliable identification ... is a turnkey solution providing mouse and keyboard ... integrate fingerprint ID solutions into their product offerings, ...
(Date:3/2/2015)... 2, 2015   Neurotechnology , a provider of ... SentiGaze Software Development Kit (SDK). The SentiGaze ... use off-the-shelf webcams to track eye movements and generate ... monitor. Heatmaps can be used for applications such as ... advertising. The SDK can also be used to develop ...
(Date:2/24/2015)... YORK , Feb. 24, 2015 This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... classified as overweight are less likely to die over a ten ... according to a new study published today in the Journal ... taken over a decade among more than 9,200 Australian men and ... study, who were assessed for their health and lifestyle as part ...
... As so-called primary producers, plants use solar energy to ... process of photosynthesis works in much the same way as ... these, plant leaves must cope with variations in the level ... and his colleagues at LMU Munich have been studying how ...
... Disease Control and Prevention, the U.S. Food and Drug Administration ... Service are investigating a multistate outbreak of Salmonella Montevideo. ... Iowa confirmed on Monday, Jan. 25, that this strain of ... people in 39 states (one case in Iowa) since July ...
Cached Biology News:'Overweight' adults age 70 or older are less likely to die over a 10-year period 2Green energy management 2Green energy management 3Hygienic Lab at U. Iowa first to confirm salmonella in nationwide outbreak 2
... NEW VSOS-4P, all Programmable and Digital Orbital Shaker. ... been redesigned to make every day use even ... memory for up to 4 different programs. Its ... your program. Furthermore, the VSOS-4P has a pulse ...
... Fixed clamp trays ... easy Magnetic drive ... rpm 25 mm amplitude ... 25 ml to 2000 ml, including ...
... System is a fluorescent microscopy-based imaging system ... cells and automatically calculates cell viability, in ... routine function, the variability associated with the ... eliminated. Using the EasyCount ViaSure Kit, up ...
... 2-3x faster than western blotting. Get results ... Direct on gel detection. Eliminates the need ... detection methods. All reagents are ready-to-use. No ... to use. Only 2 reagents required. Guarantees a ...
Biology Products: